Your browser has javascript turned off or blocked. This will lead to some parts of our website to not work properly or at all. Turn on javascript for best performance.

The browser you are using is not supported by this website. All versions of Internet Explorer are no longer supported, either by us or Microsoft (read more here: https://www.microsoft.com/en-us/microsoft-365/windows/end-of-ie-support).

Please use a modern browser to fully experience our website, such as the newest versions of Edge, Chrome, Firefox or Safari etc.

Default user image.

Pia Burman

Physician

Default user image.

Temozolomide therapy for aggressive pituitary tumours – current understanding and future perspectives

Author

  • Pia Burman
  • Lydia Lamb
  • Ann McCormack

Summary, in English

The use of temozolomide (TMZ) for the management of aggressive pituitary tumours (APT) has revolutionised clinical practice in this field with significantly improved clinical outcomes and long-term survival. Its use is now well established however a large number of patients do not respond to treatment and recurrence after cessation of TMZ is common. A number of challenges remain for clinicians such as appropriate patient selection, treatment duration and the role of combination therapy. This review will examine the use of TMZ to treat APT including mechanism of action, treatment regimen and duration; biomarkers predicting response to treatment and patient selection; and current evidence for administration of TMZ in combination with other agents.

Department/s

  • Genomics, Diabetes and Endocrinology

Publishing year

2020-03-09

Language

English

Pages

263-276

Publication/Series

Reviews in Endocrine and Metabolic Disorders

Volume

21

Issue

2

Document type

Journal article review

Publisher

Springer

Topic

  • Urology and Nephrology

Keywords

  • Aggressive pituitary tumour
  • Biomarker
  • Combination therapy
  • Pituitary carcinoma
  • Temozolomide

Status

Published

Research group

  • Genomics, Diabetes and Endocrinology

ISBN/ISSN/Other

  • ISSN: 1389-9155